Genpraz DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the management of gastroesophageal reflux disease (GERD), acid peptic disorders, and related gastrointestinal conditions. Rabeprazole, a proton pump inhibitor, acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion and promoting mucosal healing. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility and accelerates gastric emptying, providing symptomatic relief from nausea, vomiting, bloating, and discomfort associated with delayed gastric emptying. The synergistic action of these two agents offers effective control of acid-related symptoms while improving gastric motility, making Genpraz DSR Capsule suitable for patients with erosive esophagitis, non-ulcer dyspepsia, and functional dyspepsia. It is generally well tolerated, but caution is advised in patients with cardiac arrhythmias, liver impairment, or those taking medications that prolong the QT interval. Genpraz DSR should be administered as prescribed by a healthcare professional, typically once daily before meals, and is not recommended for long-term use without medical supervision. Regular monitoring and adherence to prescribed dosage enhance therapeutic outcomes and minimize adverse effects.